The S1 receptor is getting a stunning amount of research attention and is showing a lot of therapeutic target potential. The question for us of course is do our compounds agonize it in a beneficial manner. That requires more research and, of course, clinical confirmation. Looking forward to Part B results.
Correct. Dr. M stated during the shareholders mtg that Sigma-1 acts as a cell chaperone throughout the body. They have seen laboratory results that indicate heart health may be improved.
News 
Market Data 
Discover 
